Daniel A. Arber
YOU?
Author Swipe
View article: Characterization of chromosome 5 aberrations in <i>TP53</i> mutated myeloid neoplasms with ≥5% blasts: An International <i>TP53</i> Investigators Network (iTiN) study
Characterization of chromosome 5 aberrations in <i>TP53</i> mutated myeloid neoplasms with ≥5% blasts: An International <i>TP53</i> Investigators Network (iTiN) study Open
Background Isolated chromosome 5/5q losses (–5/5q) without TP53 mutations are associated with favorable outcomes in myeloid neoplasms (MN) with <5% blasts. However, the clinical implication of concurrent −5/5q and TP53 aberrations in MN wi…
View article: Chronic myelomonocytic leukemia in the young (aged 50 years and younger): Divergent clinical and molecular characteristics from the elderly
Chronic myelomonocytic leukemia in the young (aged 50 years and younger): Divergent clinical and molecular characteristics from the elderly Open
Background Chronic myelomonocytic leukemia (CMML) is largely a disease of individuals older than 50 years; its occurrence in patients aged 50 years and younger is rare. The authors sought to characterize the clinicopathologic features and …
View article: MAPS-R: International consensus classification-guided revision of the mayo alliance prognostic system for systemic mastocytosis
MAPS-R: International consensus classification-guided revision of the mayo alliance prognostic system for systemic mastocytosis Open
Background: The International Consensus Classification (ICC) for systemic mastocytosis (SM) recognizes mast cell leukemia (MCL) and SM with associated myeloid neoplasm (SM-AMN) as distinct categories of advanced SM (SM-Adv; Arber et al. Bl…
View article: Acute Leukemias of Ambiguous Lineage With <i>RUNX1</i> Mutations Show Similar Prognosis Compared to Acute Myeloid Leukemia With <i>RUNX1</i> Mutations: A Study From the Bone Marrow Pathology Group
Acute Leukemias of Ambiguous Lineage With <i>RUNX1</i> Mutations Show Similar Prognosis Compared to Acute Myeloid Leukemia With <i>RUNX1</i> Mutations: A Study From the Bone Marrow Pathology Group Open
The World Health Organization (WHO) 5th Edition and International Consensus Classification (ICC) have continued to delineate more genetically defined acute leukemias. Both recognize genetic aberrations associated with myelodysplastic syndr…
View article: Systemic Mastocytosis in 910 Patients: Prognostic Contribution of the International Consensus Classification in the Context of the Mayo Alliance Prognostic System
Systemic Mastocytosis in 910 Patients: Prognostic Contribution of the International Consensus Classification in the Context of the Mayo Alliance Prognostic System Open
The current study includes 910 patients with systemic mastocytosis (SM) seen at the Mayo Clinic from 1968 to 2024. The primary objective was to examine the prognostic contribution of the International Consensus Classification (ICC), in the…
View article: Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort
Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort Open
The World Health Organization (WHO-5) and International Consensus Classification (ICC) acknowledge the poor prognosis of TP53 -mutated ( TP53 mut ) myeloid neoplasm (MN). However, there are substantial differences between the two classific…
View article: Role of allo-HCT in “nonclassical” MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT
Role of allo-HCT in “nonclassical” MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT Open
“Nonclassical” myeloproliferative neoplasms (MPNs) and myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) represent a heterogeneous group of malignancies characterized by a wide range of clinical manifestations. Unlike classical MPNs,…
View article: Evidence-based risk stratification of myeloid neoplasms harboring <i>TP53</i> mutations
Evidence-based risk stratification of myeloid neoplasms harboring <i>TP53</i> mutations Open
This retrospective analysis aimed to provide evidence-based risk stratification of TP53-mutated (TP53mut) myeloid neoplasms (MNs). Of 580 MNs harboring TP53mut with variant allele frequency (VAF) ≥2%, 219 (37.8%), 194 (33.4%), 92 (15.9%), …
View article: Multihit <scp><i>TP53</i></scp> Mutations in Myeloproliferative Neoplasms and Acute Myeloid Leukemia: Comparative Analysis of Survival and Risk Factors in 142 Informative Cases
Multihit <span><i>TP53</i></span> Mutations in Myeloproliferative Neoplasms and Acute Myeloid Leukemia: Comparative Analysis of Survival and Risk Factors in 142 Informative Cases Open
A total of 142 patients with myeloproliferative neoplasms (MPNs) or acute myeloid leukemia (AML) associated with multihit TP53 mutations (m TP53 MUT ) were accessed from the Mayo Clinic database and included (i) chronic phase MPN (MPN‐CP; …
View article: <scp><i>TP53</i></scp>‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management
<span><i>TP53</i></span>‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management Open
Alterations in the tumor suppressor gene TP53 are common in human cancers and are associated with an aggressive nature. Approximately 8%–12% of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) harbor TP53 mutations ( TP53 mu…
View article: Classification of Myelodysplastic, Myeloproliferative, and Myelodysplastic/Myeloproliferative Neoplasms: The Past, Present, and Future
Classification of Myelodysplastic, Myeloproliferative, and Myelodysplastic/Myeloproliferative Neoplasms: The Past, Present, and Future Open
With the recent publication of new classification systems of hematopoietic neoplasms, understanding how recognition of disease entities has occurred over time and the subsequent development of formal disease classifications is of importanc…
View article: <scp><i>TP53</i></scp> Mutations in Myeloproliferative Neoplasms: Context‐Dependent Evaluation of Prognostic Relevance
<span><i>TP53</i></span> Mutations in Myeloproliferative Neoplasms: Context‐Dependent Evaluation of Prognostic Relevance Open
The clinical relevance of TP53 mutations ( TP53 MUT ) in myeloproliferative neoplasms (MPN) and their prognostic interaction with MPN subtype designation has not been systematically studied. In the current study, 114 patients with MPN harb…
View article: Clinical, immunophenotypic, and genomic findings of acute myeloid leukemia with RAM immunophenotype: Comparison with other CD56‐positive acute leukemias
Clinical, immunophenotypic, and genomic findings of acute myeloid leukemia with RAM immunophenotype: Comparison with other CD56‐positive acute leukemias Open
Background Acute myeloid leukemia (AML) with RAM immunophenotype is a newly recognized high‐risk AML immunophenotypic subcategory characterized by blasts with bright expression of CD56 and weak to absent expression of CD45, HLA‐DR, and CD3…
View article: What have we learned about TP53-mutated acute myeloid leukemia?
What have we learned about TP53-mutated acute myeloid leukemia? Open
TP53 is a tumor suppressor gene frequently mutated in human cancers and is generally associated with poor outcomes. TP53 mutations are found in approximately 5% to 10% of patients with de novo acute myeloid leukemia (AML), more frequently …
View article: <i>TP53</i> Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance
<i>TP53</i> Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance Open
Background The prognostic relevance of TP53 mutations (TP53MT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) has been extensively studied and the information accessed for defining the new International Consensus Class…
View article: Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial
Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial Open
Introduction: Based on a donor versus no-donor analysis, UKALLXII/E2993 showed a survival benefit for adults with acute lymphoblastic leukemia (ALL) who underwent allogeneic hematopoietic cell transplantation (alloHCT) in first complete re…
View article: Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults Open
The addition of blinatumomab to consolidation chemotherapy in adult patients in MRD-negative remission from BCP-ALL significantly improved overall survival. (Funded by the National Institutes of Health and others; E1910 ClinicalTrials.gov …
View article: Supplementary Raw Data Tables from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis
Supplementary Raw Data Tables from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis Open
Raw patient and scRNA-seq data
View article: Data from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis
Data from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis Open
Myeloid neoplasms arise from preexisting clonal hematopoiesis (CH); however, the role of CH in the pathogenesis of acute lymphoblastic leukemia (ALL) is unknown. We found that 18% of adult ALL cases harbored TP53, and 16% had myeloid CH-as…
View article: Supplementary Figures 1-19 from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis
Supplementary Figures 1-19 from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis Open
Supplemental Figure 1. WHO/ICC subtypes for the B-ALL cohort.Supplemental Figure 2. Lymphoid clonal hematopoiesis (CH) mutations are less common in adults with ALL.Supplemental Figure 3. Blast percentage in the pre-treatment sample and det…
View article: Supplementary Raw Data Tables from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis
Supplementary Raw Data Tables from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis Open
Raw patient and scRNA-seq data
View article: Supplementary Tables 1-11 from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis
Supplementary Tables 1-11 from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis Open
Supplemental Table 1. List of DNA gene mutations tested in diagnostic tumor samples of our ALL cohort.Supplemental Table 2. List of 80 genes with RNA sequencing coverage.Supplemental Table 3. Demographics of 400 adult ALL cases.Supplementa…
View article: Data from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis
Data from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis Open
Myeloid neoplasms arise from preexisting clonal hematopoiesis (CH); however, the role of CH in the pathogenesis of acute lymphoblastic leukemia (ALL) is unknown. We found that 18% of adult ALL cases harbored TP53, and 16% had myeloid CH-as…